11.15.12
International Stem Cell Corporation, a California-based biotechnology company, is rolling out Lifeline Eye Firming Complex to select spas and medical clinics on November 15, 2012.
Lifeline Eye Firming Complex is said to complement the current anti-aging product line introduced in November 2010 and available in selected luxury spas, medical offices and online.
The new Eye Firming Complex includes a human stem cell extract developed and patented by International Stem Cell Corporation which is used in the Company's anti-aging Day and Night serums.
"This addition to our skincare line has been highly anticipated," says Donna Queen, president of Lifeline Skin Care. "An eye treatment was the No. 1 request by our customers."
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell.
Lifeline Eye Firming Complex is said to complement the current anti-aging product line introduced in November 2010 and available in selected luxury spas, medical offices and online.
The new Eye Firming Complex includes a human stem cell extract developed and patented by International Stem Cell Corporation which is used in the Company's anti-aging Day and Night serums.
"This addition to our skincare line has been highly anticipated," says Donna Queen, president of Lifeline Skin Care. "An eye treatment was the No. 1 request by our customers."
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell.